NO20050540L - Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-ami - Google Patents

Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-ami

Info

Publication number: NO20050540L
Authority: NO; Norway
Prior art keywords: methyloctyl; fluorobenzyl; dihydroxy; carboxylic acid; carbam
Prior art date: 2002-08-12

Application number

NO20050540A

Other languages

English (en)

Norwegian (no)

Inventor

Clifford Nathaniel Meltz

Zheng Jane Li

Christopher Stanley Poss

John Charles Kath

Zhengong Bryan Li

Eric Brock Mcelroy

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-12

Filing date

2005-01-31

Publication date

2005-03-10

2005-01-31 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-03-10 Publication of NO20050540L publication Critical patent/NO20050540L/no

Links

125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 title 1
150000001412 amines Chemical class 0.000 title 1
UPUZGXILYFKSGE-UHFFFAOYSA-N quinoxaline-2-carboxylic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CN=C21 UPUZGXILYFKSGE-UHFFFAOYSA-N 0.000 title 1
RALCLUSHFOIHOL-UHFFFAOYSA-N 5-amino-6-(3-fluorophenyl)-4-hydroxy-2-(3-hydroxy-3-methylbutyl)hexanamide Chemical compound CC(C)(O)CCC(C(N)=O)CC(O)C(N)CC1=CC=CC(F)=C1 RALCLUSHFOIHOL-UHFFFAOYSA-N 0.000 abstract 1
102100031172 C-C chemokine receptor type 1 Human genes 0.000 abstract 1
101710149814 C-C chemokine receptor type 1 Proteins 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
239000013078 crystal Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Plural Heterocyclic Compounds (AREA)

NO20050540A 2002-08-12 2005-01-31 Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-ami NO20050540L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40321602P	2002-08-12	2002-08-12
PCT/IB2003/003464 WO2004014875A1 (fr)	2002-08-12	2003-07-31	Formes cristallines d'acide quinoxaline-2-carboxylique [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide

Publications (1)

Publication Number	Publication Date
NO20050540L true NO20050540L (no)	2005-03-10

Family

ID=31715961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20050540A NO20050540L (no)	2002-08-12	2005-01-31	Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-ami

Country Status (22)

Country	Link
US (1)	US20040072834A1 (fr)
EP (1)	EP1539715A1 (fr)
JP (1)	JP2005538130A (fr)
AP (1)	AP2005003226A0 (fr)
AR (1)	AR040839A1 (fr)
AU (1)	AU2003250450A1 (fr)
BR (1)	BR0313378A (fr)
CA (1)	CA2494776A1 (fr)
EC (1)	ECSP055588A (fr)
GT (1)	GT200300169A (fr)
IL (1)	IL166548A0 (fr)
IS (1)	IS7674A (fr)
MX (1)	MXPA05001781A (fr)
NO (1)	NO20050540L (fr)
OA (1)	OA12894A (fr)
PA (1)	PA8580401A1 (fr)
PE (1)	PE20040866A1 (fr)
TN (1)	TNSN05035A1 (fr)
TW (1)	TW200407316A (fr)
UY (1)	UY27928A1 (fr)
WO (1)	WO2004014875A1 (fr)
ZA (1)	ZA200500768B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5731538B2 (ja)	2009-12-23	2015-06-10	アイアンウッドファーマシューティカルズインコーポレイテッド	Ｃｒｔｈ２モジュレーター
WO2012009137A1 (fr)	2010-07-12	2012-01-19	Ironwood Pharmaceuticals, Inc.	Modulateurs de crth2
US20130259830A1 (en)	2010-07-12	2013-10-03	Ironwood Pharmaceuticals, Inc.	Crth2 modulators
CN102276539B (zh) *	2011-06-29	2013-08-14	赵雪梅	一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE640616A (fr) *	1962-12-19
US3492397A (en) *	1967-04-07	1970-01-27	Warner Lambert Pharmaceutical	Sustained release dosage in the pellet form and process thereof
US4060598A (en) *	1967-06-28	1977-11-29	Boehringer Mannheim G.M.B.H.	Tablets coated with aqueous resin dispersions
US3538214A (en) *	1969-04-22	1970-11-03	Merck & Co Inc	Controlled release medicinal tablets
US4173626A (en) *	1978-12-11	1979-11-06	Merck & Co., Inc.	Sustained release indomethacin
WO1998038167A1 (fr) *	1997-02-26	1998-09-03	Pfizer Inc.	Derives amines de l'acide heteroaryle-hexanoique, leur preparation, et leur utilisation comme inhibiteurs selectifs du mip-1 alpha par fixation a son recepteur ccr1
UA57824C2 (uk) *	1998-02-05	2003-07-15	Пфайзер Продактс Інк.	Похідні дигідроксигексанової кислоти, фармацевтична композиція, що їх містить (варіанти), та спосіб лікування (варіанти)

2003
- 2003-07-31 WO PCT/IB2003/003464 patent/WO2004014875A1/fr not_active Ceased
- 2003-07-31 AP AP2005003226A patent/AP2005003226A0/xx unknown
- 2003-07-31 CA CA002494776A patent/CA2494776A1/fr not_active Abandoned
- 2003-07-31 OA OA1200500028A patent/OA12894A/en unknown
- 2003-07-31 MX MXPA05001781A patent/MXPA05001781A/es not_active Application Discontinuation
- 2003-07-31 JP JP2004527195A patent/JP2005538130A/ja active Pending
- 2003-07-31 BR BR0313378-8A patent/BR0313378A/pt not_active Application Discontinuation
- 2003-07-31 AU AU2003250450A patent/AU2003250450A1/en not_active Abandoned
- 2003-07-31 EP EP03784383A patent/EP1539715A1/fr not_active Withdrawn
- 2003-08-05 UY UY27928A patent/UY27928A1/es not_active Application Discontinuation
- 2003-08-06 GT GT200300169A patent/GT200300169A/es unknown
- 2003-08-06 TW TW092121503A patent/TW200407316A/zh unknown
- 2003-08-08 US US10/637,475 patent/US20040072834A1/en not_active Abandoned
- 2003-08-08 AR AR20030102881A patent/AR040839A1/es unknown
- 2003-08-08 PE PE2003000794A patent/PE20040866A1/es not_active Application Discontinuation
- 2003-08-12 PA PA20038580401A patent/PA8580401A1/es unknown
2005
- 2005-01-26 ZA ZA200500768A patent/ZA200500768B/xx unknown
- 2005-01-27 IL IL16654805A patent/IL166548A0/xx unknown
- 2005-01-27 IS IS7674A patent/IS7674A/is unknown
- 2005-01-31 NO NO20050540A patent/NO20050540L/no unknown
- 2005-02-03 EC EC2005005588A patent/ECSP055588A/es unknown
- 2005-02-11 TN TNP2005000035A patent/TNSN05035A1/fr unknown

Also Published As

Publication number	Publication date
IS7674A (is)	2005-01-27
TW200407316A (en)	2004-05-16
ECSP055588A (es)	2005-04-18
ZA200500768B (en)	2006-07-26
AP2005003226A0 (en)	2005-03-31
JP2005538130A (ja)	2005-12-15
BR0313378A (pt)	2005-07-12
UY27928A1 (es)	2004-03-31
OA12894A (en)	2006-10-13
PA8580401A1 (es)	2004-02-16
CA2494776A1 (fr)	2004-02-19
WO2004014875A1 (fr)	2004-02-19
US20040072834A1 (en)	2004-04-15
GT200300169A (es)	2004-05-12
MXPA05001781A (es)	2005-04-25
PE20040866A1 (es)	2004-11-26
IL166548A0 (en)	2006-01-15
EP1539715A1 (fr)	2005-06-15
AR040839A1 (es)	2005-04-20
AU2003250450A1 (en)	2004-02-25
TNSN05035A1 (fr)	2007-05-14

Publication	Publication Date	Title
WO2007059257A8 (fr)	2008-06-19	Inhibiteurs erbb
WO2003057698A3 (fr)	2003-07-31	Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
WO2005123703A3 (fr)	2006-10-12	Nouveauc derives alkynyl servant de modulateurs de recepteurs de glutamate metabotropiques
IN2006KO01346A (fr)	2015-09-04
CA2443724A1 (fr)	2002-11-21	Composes arylsulfonamide pour le traitement de l'obesite, de diabetes de type ii et de troubles du systeme nerveux central
WO2002098865A3 (fr)	2003-02-27	Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
WO2004002419A3 (fr)	2004-06-03	Sels de phospate de carvedilol et/ou solvates de celui-ci, compositions et/ou methodes de traitement associees
WO2006073973A3 (fr)	2008-12-04	Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
NO20082136L (no)	2008-06-30	1,5-substituerte indol-2-yl-amidderivater
WO2005034866A3 (fr)	2005-07-28	Preparation d'azabenzimidazoles trisubstitues en position 1,6,7 servant d'inhibiteurs des kinases
NO20051503L (no)	2005-03-21	Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
WO2004094386A8 (fr)	2005-02-17	Utilisation d'amides d'acide isoquinoline-5-sulfonique comme inhibiteurs de l'akt (proteine kinase b)
MXPA05004621A (es)	2005-06-08	Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
WO2005086656A3 (fr)	2005-12-29	Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2004084943A8 (fr)	2004-12-23	Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
WO2004052858A3 (fr)	2004-08-12	Inhibiteurs d'absorption de monoamine
WO2004019879A3 (fr)	2004-06-03	Composes du type motilide
WO2004110385A3 (fr)	2005-01-27	Modulateurs du recepteur des glucocorticoides et procede associe
NO20050540L (no)	2005-03-10	Krystallinske former av kinoxalin-2-karboksylsyre [4-karbamT-1-(3-fluorbenzyl)-2,7-dihydroksy-7-metyloktyl]-ami
NO20061575L (no)	2006-06-09	Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
WO2003072537A3 (fr)	2003-12-18	Inhitibteurs selectifs de la proteine tyrosine phosphatatase
WO2005077332A3 (fr)	2006-07-27	Formes posologiques stables de gabapentine pour usage oral et a liberation prolongee, et procede de preparation associe
WO2007119120A3 (fr)	2008-02-14	Formes polymorphes cristallines de chlorhydrate d'olopatadine et leurs procédés de préparation
WO2005112923A3 (fr)	2006-09-14	Dérivés de 5-anilino-4-hétéroarylpyrazole utiles pour le traitement du diabete
ATE373476T1 (de)	2007-10-15	Verwendung von 2-thia-dibenzo(e,h)azulenen zur behandlung und prävention von erkrankungen und störungen des zentralen nervensystems